Finanza

Notizie Discussioni Tecnici Previsione Stagionalità

Utile netto al lordo delle operazioni dismesse su Verve Therapeutics, Inc..

Dati annuali

2020

2021

2022

2023

2024

TTM

‪‪−220,00 M‬‬

‪‪−165,00 M‬‬

‪‪−110,00 M‬‬

‪‪−55,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

TTM

‪‪−198,71 M‬‬

‪0,00‬

‪0,00‬%

2024

‪‪−198,71 M‬‬

+‪‪1,36 M‬‬

+‪0,68‬%

2023

‪‪−200,07 M‬‬

‪‪−42,68 M‬‬

‪−27,12‬%

2022

‪‪−157,39 M‬‬

‪‪−37,07 M‬‬

‪−30,81‬%

2021

‪‪−120,31 M‬‬

‪‪−74,61 M‬‬

‪−163,25‬%

2020

‪‪−45,70 M‬‬

‪‪−26,41 M‬‬

‪−136,85‬%

Dati trimestrali

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−60,00 M‬‬

‪‪−45,00 M‬‬

‪‪−30,00 M‬‬

‪‪−15,00 M‬‬

‪0,00‬

Periodo

Valore

Variazione

Variazione %

Q4 '24

‪‪−50,03 M‬‬

+‪‪98,00 K‬‬

+‪0,20‬%

Q3 '24

‪‪−50,13 M‬‬

‪‪−328,00 K‬‬

‪−0,66‬%

Q2 '24

‪‪−49,80 M‬‬

‪‪−1,07 M‬‬

‪−2,19‬%

Q1 '24

‪‪−48,74 M‬‬

‪‪−384,00 K‬‬

‪−0,79‬%

Q4 '23

‪‪−48,35 M‬‬

‪‪−2,59 M‬‬

‪−5,67‬%

Q3 '23

‪‪−45,76 M‬‬

+‪‪8,22 M‬‬

+‪15,24‬%

Q2 '23

‪‪−53,98 M‬‬

‪‪−2,01 M‬‬

‪−3,86‬%

Q1 '23

‪‪−51,98 M‬‬

‪‪−10,89 M‬‬

‪−26,51‬%

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20